Scientific Review Board

Members from two different advisory groups, the Scientific Review Board and the Business Advisory Board, review all grant applications submitted to the ADDF. The Scientific Review Board is composed of over 150 scientists who encompass various areas of expertise within Alzheimer’s research.

  • Pankaj Agarwal, PhD
    GlaxoSmithKline

  • Larry D. Altstiel, MD, PhD
    Pfizer Inc

  • Ottavio Arancio, MD, PhD
    Columbia University

  • Kelly Bales, PhD
    Pfizer Inc

  • Nir Barzilai, MD
    Albert Einstein College of Medicine

  • Guriq Basi, PhD
    Elan Pharmaceuticals

  • Paul E. Bendheim, MD
    BrainSavers LLC

  • David A. Bennett, MD
    Rush University Medical Center

  • Jennifer Bizon, PhD
    McKnight Brain Research Foundation

  • Chas Bountra, PhD
    University of Oxford

  • Adam Boxer, MD, PhD
    University of California, San Francisco

  • Roberta Diaz Brinton, PhD
    University of Southern California

  • Tilmann Brotz, PhD
    Konzept Drug Development Consulting

  • Kurt Brunden, PhD
    University of Pennsylvania

  • Thomas Chung, PhD
    Sanford-Burnham Medical Research Institute